Open an account

Agenus

AGEN · NASDAQ

$6.42+$0.24 (+3.88%)TodayMarket closed ·
Prev close $6.18

About AGEN

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. The company is headquartered in Lexington, Massachusetts and currently employs 81 full-time employees. The company went IPO on 2000-02-04. The firm is focused on expanding patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Its I-O portfolio is driven by several platforms and programs, which include multiple antibody discovery platforms, antibody candidate programs, its saponin-based vaccine adjuvant platform, and a pipeline of novel allogeneic invariant natural killer T cell (iNKT) therapies for treating cancer and other immune-mediated diseases, controlled by MiNK. Its antibody candidate programs include botensilimab (BOT) and balstilimab (BAL) (a PD-1 blocking antibody). The firm has secured committed manufacturing capacity to support BOT+BAL supply needs for its clinical trials, global access programs and future commercialization.

Employees
81
Headquarters
Lexington, Massachusetts
Listed
Feb 4, 2000
Sector
Health Care
Industry
Biotechnology
Website
agenusbio.com

AGEN key statistics

Market cap
289.94M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.04M
Volume
827.32K
Open price
$6.10
High today
$6.58
Low today
$6.05
52 Week high
$10.31
52 Week low
$2.71

Agenus (AGEN) at a glance

Agenus (AGEN) last traded at $6.42, with a market cap of 289.94M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $6.05 and $6.58. The current price is 6.1% above the day's low and 2.4% below its high.

Volume so far is 827.32K shares, below the average of 1.04M shares a day.

Over the past year Agenus has ranged from $2.71 to $10.31, and now sits 49% of the way up that range.

Agenus met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$0.01 per share against an estimate of $0.051.

The average analyst price target is $26.86, 318.4% above the current price, from 4 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 4 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 5 analystsAvg $26.86
Low
$14.14
Now
$6.42
High
$42.00

AGEN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 43.8% on average.

  1. Q3 FY24: reported -$3.08 per share against an estimate of -$2.38
  2. Q4 FY24: reported -$2.04 per share against an estimate of -$2.59
  3. Q1 FY25: reported -$1.03 per share against an estimate of -$1.69
  4. Q2 FY25: reported -$1.00 per share against an estimate of $1.38
  5. Q3 FY25: reported $1.94 per share against an estimate of $2.02
  6. Q4 FY25: reported -$0.311 per share against an estimate of -$1.07
  7. Q1 FY26: reported $0.00 per share against an estimate of $2.14
  8. Q2 FY26: reported -$0.01 per share against an estimate of $0.051

AGEN news

  • Press releaseBusiness Wire

    Agenus to Participate in Chardan’s 10th Annual Healthcare Investor Conference

  • Press releaseBusiness Wire

    Armenia Grants First Marketing Authorizations for Agenus’ BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer

  • Press releaseBusiness Wire

    Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026

  • Press releaseBusiness Wire

    Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026

  • Press releaseBusiness Wire

    Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026

  • Press releaseBusiness Wire

    Agenus to Participate in Upcoming September Investor Conferences

  • Press releaseBusiness Wire

    Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism

  • Press releaseBusiness Wire

    Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer

Similar companies

Companies in the same industry as Agenus

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.